OncoResponse Obtains $19,499,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    909 Fannin Houston, TX 77024 USA
  • Company Description
    OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The investment by Baxalta brings the total Series A to $12.5 million and will be used to support OncoResponse’s ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.
  • M&A Terms
  • Venture Investor
    Baxalta Ventures
  • Venture Investor

Trending on Xconomy